Ovitrelle® 250 µg/0.5 ml : Drug preparation and administration

https://www.institutobernabeu.com/en/ The active principle in Ovitrelle is recombinant hCG human chorionic gonadotropin hormone. This pharmaceutical drug completes oocyte maturation and triggers ovulation around 36 hours after it has been administered. Depending on if we wish to perform artificial insemination (AI) or in vitro fertilisation (IVF), it is used one way or another. It must always be administered at the same time on each occasion. As ovulation approaches, symptoms can resemble the symptoms that women experience over the days prior to menstruation. This medicine is administered subcutaneously. In other words, it is injected into the skin, generally around the abdomen.